The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Jun. 14, 2022
Applicant:
Cancer Therapeutics Laboratories, Inc., Los Angeles, CA (US);
Inventors:
Alan Epstein, Los Angeles, CA (US);
Peisheng Hu, Los Angeles, CA (US);
Assignee:
CANCER THERAPEUTICS LABORATORIES, INC., Los Angeles, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61P 31/18 (2006.01); C07K 16/00 (2006.01); C07K 16/44 (2006.01); C12N 5/077 (2010.01); C12N 15/10 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); A61K 39/00 (2013.01); A61K 47/6801 (2017.08); A61K 51/10 (2013.01); C07K 16/005 (2013.01); C12N 15/1058 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract
Humanized monoclonal anti-nuclear antibodies with enhanced binding affinity and tumor uptake are presented. Particularly preferred antibodies are site-directed mutants of H-CDR3 with up to about 8-fold improvement in affinity as compared to the non-humanized non-mutated form. In further preferred aspects, such humanized antibodies are employed in tumor necrosis targeted delivery of immune modulators, immune effectors, and other therapeutic or diagnostic agents.